This editorial refers to 'Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a metaanalysis of 8567 patients in the 11 trials' † , by M.J. Shun-Shin et al., on page 1738.
Systolic heart failure is a life-threatening disease. Despite best medical therapy, a diagnosis of systolic heart failure carries with it a 5-year survival equivalent to that of colorectal cancer. 1 Part of this excess death is due to sudden cardiac death and, to reduce the risk of this, guidelines recommend the implantation of a defibrillator. Defibrillators do one thing: they reduce sudden cardiac death, whether caused by ventricular arrhythmia or severe bradycardia. However, most patients with systolic heart failure do not die from arrhythmic death but from non-sudden cardiac death or non-cardiac causes, such as colorectal cancer. Consequently, it stands to reason that the effect of defibrillators on all-cause mortality depend on the patients' risk of dying and the proportion of this risk attributable to sudden cardiac death vs. other causes. The proportion of patients that die from sudden cardiac death compared with other causes differs depending on age, severity of heart failure, co-morbidities, and frailty, as well as the aetiology of heart failure.
In this issue of the Jouranl, Shun-Shin et al. present a meta-analysis of defibrillators for primary prevention of death in patients with systolic heart failure. 2 The main reason for this is the recent publication of a neutral effect on all-cause death in the Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) trial. 3 The conclusion of the metaanalysis is that defibrillators do work. Taken as a whole, defibrillators reduce mortality in patients with systolic heart failure irrespective of aetiology, and, when looked at separately, defibrillators work in both patients with and without ischaemic heart disease as the primary aetiology of heart failure. For ischaemic heart disease, the mortality-reducing effect of defibrillators is a robust finding from both meta-analyses and individual trials, but for non-ischaemic aetiology no single trial has ever been able to document an effect of defibrillators on all-cause mortality in a pre-specified hypothesis [although, as first reported >10 years ago in abstract form and rediscovered by Shun-Shin et al., a significant effect of adding a defibrillator to cardiac resynchronization therapy was found among patients with non-ischaemic aetiology in a post-hoc analysis of the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) study 4, 5 ]. Given the totality of evidence and the underlying plausible effect mechanism, it seems reasonable to conclude that in the average patient, defibrillators do work. However, not all patients benefit from a defibrillator. Patients who are at a low risk of dying from sudden cardiac death, either because their overall risk of death is low or because their risk of dying from something else is much larger, are not likely to benefit substantially from a defibrillator. This does not negate the findings of the new meta-analysis but does give cause to question its implications, and indeed several important questions remain unanswered. In particular, questions remain pertaining to the effect of adding a defibrillator to cardiac resynchronization therapy, the effect of defibrillators in older patients, and whether the impact of defibrillators on survival wanes over time.
The average meta-analysis patient did not receive cardiac resynchronization therapy. Cardiac resynchronization therapy effectively reduces mortality in patients with symptomatic systolic heart failure and a wide left bundle branch block by decreasing both sudden and total cardiovascular death. The vast majority of patients in the present meta-analysis did not receive cardiac resynchronization therapy even though many would possibly qualify for it according to current guidelines; the two trials that did include cardiac resynchronization therapy patients were COMPANION and DANISH, and neither demonstrated an effect of a defibrillator in addition to cardiac resynchronization therapy. There was an isolated effect in a subgroup analysis of patients with non-ischaemic aetiology in COMPANION (and a null effect in ischaemics), but this stands in contrast to the very neutral effect in this group in DANISH. The average meta-analysis patient was 63 years old. However, the impact of defibrillator implantation on all-cause death decreases with age and, in DANISH, there was no effect of a defibrillator in patients in the upper age tertile (68 years and older). 6 It does not go against common sense that there is a reduced effect of defibrillators in the elderly. With age comes an increasing risk of death from all causes. In recent registry data, where patients who received cardiac resynchronization therapy without a defibrillator were 10 years older and had more co-morbidities compared with those who also received a defibrillator, the patients without a defibrillator had a twofold increased mortality. However, almost all excess deaths in this group were non-sudden. Lastly, the average meta-analysis patient was followed up for 3 years; a defibrillator lasts 7 years. In DANISH, which had a median follow-up of 6.5 years, there was a reduced effect of defibrillator implantation over time, with the survival curves crossing at 7.5 years. In all of the trials which demonstrated an effect of a defibrillator, except the Sudden Cardiac Death in Heart Failure Trial (SCDHeFT), patients were followed up for <3 years. Consequently, we have no evidence on how a defibrillator impacts patient outcome during its entire lifetime.
The complex interaction between age, co-morbidity, duration of heart failure, aetiology, and mode of death ( Figure 1) should not be ignored when adding a treatment that is expensive and potentially also associated with severe side effects. Thus, we know that defibrillators prevent deaths, but we still need to find out who benefits from them. In fact, the results of the Danish trial may have opened the doors for also testing whether defibrillators are appropriate for all patients with heart failure due to ischaemic aetiology.
